EPICS is a drug discovery and development company that invents and develops small molecule drugs targeting RNA epigenetic mechanisms involved in cancer development. EPICS’s mission is to utilize its expertise in drug discovery and development to invent novel clinical agents targeting serious unmet medical needs in oncology. We develop products to meet high value-added endpoints. We constantly balance risk and reward in determining if and when to partner our programs.